Skip to main content
SpringerLink
Log in

Lupus Erythematosus

  • Chapter
European Handbook of Dermatological Treatments

Abstract

Several agents are approved for the treatment of systemic lupus erythematosus (SLE), including the novel monoclonal antibody belimumab, a B lymphocyte stimulator-specific inhibitor. However, no drugs have been licensed specifically for the treatment of skin manifestations of the disease. Therefore, therapeutic agents are applied off-label for patients with cutaneous lupus erythematosus (CLE), mainly based on the experience of experts. Topical corticosteroids are the mainstay of treatment for all different subtypes of the disease, but they are of limited value because of their well-known side effects, such as skin atrophy and telangiectasia. A safe and effective alternative topical treatment for CLE are the calcineurin inhibitors tacrolimus and pimecrolimus. Irrespective of the subtype of the disease, antimalarials, such as hydroxychloroquine or chloroquine, are the first-line systemic treatment for disfiguring and widespread skin manifestations. Systemic steroids can be used additionally in patients with highly acute and severe skin lesions but should be time limited due to the common side effects, such as osteoporosis. In contrast to immunosuppressive agents, such as azathioprine, cyclophosphamide, and cyclosporine, methotrexate has received more attention in the therapeutic management of skin manifestations of the disease. Further second-line treatment includes retinoids, dapsone, and mycophenolate mofetil. Other agents, such as rituximab and ustekinumab, have been used in single cases of therapy-refractory CLE and need to be evaluated in randomized controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albrecht J, Berlin JA, Braverman IM, Callen JP, Connolly MK, Costner MI, et al. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus. 2004;13:839–49.

    Article  CAS  PubMed  Google Scholar 

  • Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy. J Dermatol. 2005;32:482–6.

    Article  PubMed  Google Scholar 

  • Bacman D, Kuhn A, Ruzicka T. Dapsone and retinoids. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Berlin: Springer; 2004. p. 373–90.

    Google Scholar 

  • Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34:776–80.

    Article  CAS  PubMed  Google Scholar 

  • Bertsias G, Ioannidis JP, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195–205.

    Google Scholar 

  • Bezerra EL, Vilar MJ, da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:3073–8.

    Article  CAS  PubMed  Google Scholar 

  • Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol. 2001;137:235–6.

    CAS  PubMed  Google Scholar 

  • Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18:59–62.

    Article  CAS  PubMed  Google Scholar 

  • Bohm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology. 1997;194:307–8.

    Article  CAS  PubMed  Google Scholar 

  • Bohm I, Bruns A, Schupp G, Bauer R. ANCA-positive lupus erythematodes profundus. Successful therapy with low dosage dapsone. Hautarzt. 1998;49:403–7.

    Article  CAS  PubMed  Google Scholar 

  • Bottomley WW, Goodfield MJ. Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol. 1995;133:655–6.

    Article  CAS  PubMed  Google Scholar 

  • Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. 2012;66:571–82.

    Article  CAS  PubMed  Google Scholar 

  • Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004;62:2288–90.

    Article  CAS  PubMed  Google Scholar 

  • Cetkovska P, Pizinger K. Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol. 2006;45:320–2.

    Article  PubMed  Google Scholar 

  • Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147:1261–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383–90.

    Article  CAS  PubMed  Google Scholar 

  • Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol. 1997;24:569–72.

    Article  CAS  PubMed  Google Scholar 

  • Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol. 1982;106:105–6.

    Article  CAS  PubMed  Google Scholar 

  • Coelho A, Souto MI, Cardoso CR, Salgado DR, Schmal TR, Waddington Cruz M, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. 2005;14:434–9.

    Article  CAS  PubMed  Google Scholar 

  • Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166:616–23.

    Article  CAS  PubMed  Google Scholar 

  • Costner MI, Sontheimer RD, Provost TT. Lupus erythematosus. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams & Wilkins; 2003. p. 15–64.

    Google Scholar 

  • Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118:246–50.

    Article  CAS  PubMed  Google Scholar 

  • Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues. J Dtsch Dermatol Ges. 2012;10:167–72.

    PubMed  Google Scholar 

  • Dahl C, Johansen C, Kragballe K, Olesen AB. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. 2013;93:368–9.

    Article  PubMed  Google Scholar 

  • De Pita O, Bellucci AM, Ruffelli M, Girardelli CR, Puddu P. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997;6:415–7.

    Article  PubMed  Google Scholar 

  • De Souza A, Ali-Shaw T, Strober BE, Franks Jr AG. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. 2011;147:896–8.

    Article  PubMed  Google Scholar 

  • Diez MT, Boixeda P, Moreno C, Gonzalez JA, Zamorano ML, Olasolo PJ. Histopathology and immunohistochemistry of cutaneous lupus erythematosus after pulsed dye laser treatment. Dermatol Surg. 2011;37:971–81.

    Article  CAS  PubMed  Google Scholar 

  • Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology. J Am Acad Dermatol. 1996;34:830–6.

    Article  CAS  PubMed  Google Scholar 

  • Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum. 1978;8:33–51.

    Article  CAS  PubMed  Google Scholar 

  • Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am. 1995;21:99–115.

    CAS  PubMed  Google Scholar 

  • Dutz J, Werth VP. Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma. J Invest Dermatol. 2011;131:1968–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Erceg A, Bovenschen HJ, van de Kerkhof PC, de Jong EM, Seyger MM. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. 2009;60:626–32.

    Article  PubMed  Google Scholar 

  • Espirito Santo J, Gomes MF, Gomes MJ, Peixoto L, S CP, Acabado A, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol. 2010;38:307–18.

    Article  PubMed  Google Scholar 

  • Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology. 1994;189:425–7.

    Article  CAS  PubMed  Google Scholar 

  • Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 1986;11:102–3.

    Article  CAS  PubMed  Google Scholar 

  • Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol. 1990;29:587–90.

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev. 2009;8:343–8.

    Article  CAS  PubMed  Google Scholar 

  • Garnock-Jones KP, Perry CM. Alitretinoin: in severe chronic hand eczema. Drugs. 2009;69:1625–34.

    Article  CAS  PubMed  Google Scholar 

  • Genereau T, Chosidow O, Danel C, Cherin P, Herson S. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol. 1999;135:1124–5.

    Article  CAS  PubMed  Google Scholar 

  • Gilliam JN. The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys. 1977;6:34–70.

    Google Scholar 

  • Goldberg JW, Lidsky MD. Pulse methylprednisolone therapy for persistent subacute cutaneous lupus. Arthritis Rheum. 1984;27:837–8.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein E, Carey W. Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol. 1994;130:938–9.

    Article  CAS  PubMed  Google Scholar 

  • Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat. 2004;15:46–50.

    Article  CAS  PubMed  Google Scholar 

  • Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol. 2001;45:142–4.

    Article  CAS  PubMed  Google Scholar 

  • Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol. 2002;138:1616–8.

    Article  PubMed  Google Scholar 

  • Henderson DL, Odom JC. Laser treatment of discoid lupus (case report). Lasers Surg Med. 1986;6(12–5):44–5.

    Google Scholar 

  • High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol. 2005;52:E5.

    Article  PubMed  Google Scholar 

  • Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature. Lupus. 2013;22:932–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Holtman JH, Neustadt D, Klein J, Callen JP. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol. 1990;17:1222–5.

    CAS  PubMed  Google Scholar 

  • Huber A, Tuting T, Bauer R, Bieber T, Wenzel J. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol. 2006;155:861–2.

    Article  CAS  PubMed  Google Scholar 

  • Jemec GB, Ullman S, Goodfield M, Bygum A, Olesen AB, Berth-Jones J, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol. 2009;161:1365–70.

    Article  CAS  PubMed  Google Scholar 

  • Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;(4):CD002954.

    Google Scholar 

  • Kieu V, O’Brien T, Yap LM, Baker C, Foley P, Mason G, et al. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol. 2009;50:202–6.

    Article  PubMed  Google Scholar 

  • Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108:461–6.

    Article  CAS  PubMed  Google Scholar 

  • Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stucker M, Bader A, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004;51:407–10.

    Article  PubMed  Google Scholar 

  • Kreuter A, Hyun J, Altmeyer P, Gambichler T. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85:545–7.

    PubMed  Google Scholar 

  • Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156:1321–7.

    Article  CAS  PubMed  Google Scholar 

  • Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145:244–8.

    CAS  PubMed  Google Scholar 

  • Kuhn A, Ruzicka T. Classification of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Berlin: Springer; 2004. p. 53–8.

    Google Scholar 

  • Kuhn A, Becker-Wegerich PM, Ruzicka T, Lehmann P. Successful treatment of discoid lupus erythematosus with argon laser. Dermatology. 2000;201:175–7.

    Article  CAS  PubMed  Google Scholar 

  • Kuhn A, Specker C, Ruzicka T, Lehmann P. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2002;46:600–3.

    Article  PubMed  Google Scholar 

  • Kuhn A, Aberer E, Barde C, Foeldvari I, Haust M, Iking-Konert C. Leitlinien Kutaner Lupus Erythematodes (Entwicklungsstufe 1). In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W, editors. Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen. Berlin: ABW Wissenschaftsverlag GmbH; 2009. p. 214–57.

    Google Scholar 

  • Kuhn A, Ochsendorf F, Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus. 2010a;19:1125–36.

    Article  CAS  PubMed  Google Scholar 

  • Kuhn A, Meuth AM, Bein D, Amler S, Beissert S, Bohm M, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010b;163:898–9.

    Google Scholar 

  • Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011a;65:54–64.

    Article  CAS  PubMed  Google Scholar 

  • Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011b;65:e179–93.

    Article  PubMed  Google Scholar 

  • Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011c;65:e195–213.

    Article  PubMed  Google Scholar 

  • Kuhn A, Sigges J, Biazar C, Ruland V, Patsinakidis N, Landmann A, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol. 2014;171: 571–9.

    Google Scholar 

  • Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol. 2012;67:e123–6.

    Article  PubMed  Google Scholar 

  • Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000;39:218–22.

    Article  CAS  PubMed  Google Scholar 

  • Lampropoulos CE, Hughes GR, DC DP. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol. 2007;26:981–3.

    Article  PubMed  Google Scholar 

  • Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74.

    Article  CAS  PubMed  Google Scholar 

  • Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica. 1986;172:214–7.

    Article  CAS  PubMed  Google Scholar 

  • Lipsker D, Piette JC, Cacoub P, Godeau P, Frances C. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology. 1995;190:257–8.

    Article  CAS  PubMed  Google Scholar 

  • Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol. 2003;30:2557–62.

    CAS  PubMed  Google Scholar 

  • Ludgate MW, Greig DE. Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol. 2008;49:91–3.

    Article  PubMed  Google Scholar 

  • Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol. 1974;91:93–6.

    Article  CAS  PubMed  Google Scholar 

  • Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol. 2010;35:27–30.

    Article  CAS  PubMed  Google Scholar 

  • Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.

    Article  CAS  PubMed  Google Scholar 

  • McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg. 2001;20:14–26.

    Article  CAS  PubMed  Google Scholar 

  • McCormack LS, Elgart ML, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol. 1984;11:397–401.

    Article  CAS  PubMed  Google Scholar 

  • Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460–9.

    Article  CAS  PubMed  Google Scholar 

  • Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.

    Article  CAS  PubMed  Google Scholar 

  • Newton RC, Jorizzo JL, Solomon Jr AR, Sanchez RL, Daniels JC, Bell JD, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol. 1986;122:170–6.

    Article  CAS  PubMed  Google Scholar 

  • Nurnberg W, Algermissen B, Hermes B, Henz BM, Kolde G. Successful treatment of chronic discoid lupus erythematosus with argon laser. Hautarzt. 1996;47:767–70.

    Article  CAS  PubMed  Google Scholar 

  • Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86.

    Article  PubMed  PubMed Central  Google Scholar 

  • Piette JC, Frances C, Roy S, Papo T, Godeau P. High-dose immunoglobulins in the treatment of refractory cutaneous lupus erythematosus. Open trial in 5 cases. Arthritis Rheum. 1995;38:304.

    Google Scholar 

  • Pinto-Almeida T, Sanches M, Alves R, Selores M. Vesico-bullous subacute cutaneous lupus erythematosus–an uncommon entity successfully treated with dapsone and hydroxychloroquine. Dermatol Online J. 2012;18:13.

    PubMed  Google Scholar 

  • Pisoni CN, Karim Y, Cuadrado MJ. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus. 2005;14 Suppl 1:s9–11.

    Article  CAS  PubMed  Google Scholar 

  • Polet H. The effects of lysosomotropic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes. J Cell Physiol. 1985;122:415–23.

    Article  CAS  PubMed  Google Scholar 

  • Raulin C, Schmidt C, Hellwig S. Cutaneous lupus erythematosus-treatment with pulsed dye laser. Br J Dermatol. 1999;141:1046–50.

    Article  CAS  PubMed  Google Scholar 

  • Richardson TT, Cohen PR. Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis. 2000;66:183–8.

    CAS  PubMed  Google Scholar 

  • Richez C, Dumoulin C, Schaeverbeke T. Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol. 2005;32:760–1.

    PubMed  Google Scholar 

  • Risselada AP, Kallenberg CG. Therapy-resistant lupus skin disease successfully treated with rituximab. Rheumatology (Oxford). 2006;45:915–6.

    Article  CAS  Google Scholar 

  • Rodriguez-Castellanos MA, Barba Rubio J, Barba Gomez JF, Gonzales Mendoza A. Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol. 1995;131:620–1.

    Article  CAS  PubMed  Google Scholar 

  • Roenigk Jr HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980;25:281–5.

    PubMed  Google Scholar 

  • Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol. 1981;104:53–6.

    Article  CAS  PubMed  Google Scholar 

  • Ruzicka T, Meurer M, Braun-Falco O. Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol. 1985;65:324–9.

    CAS  PubMed  Google Scholar 

  • Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol. 1988;124:897–902.

    Article  CAS  PubMed  Google Scholar 

  • Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992;127:513–8.

    Article  CAS  PubMed  Google Scholar 

  • Sardy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301:93–8.

    Article  CAS  PubMed  Google Scholar 

  • Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol. 2002;147:174–8.

    Article  CAS  PubMed  Google Scholar 

  • Shah A, Albrecht J, Bonilla-Martinez Z, Okawa J, Rose M, Rosenbach M, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145:303–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991;24:49–52.

    Article  CAS  PubMed  Google Scholar 

  • Sticherling M. Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus. Biologics. 2011;5:21–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Stratigos AJ, Antoniou C, Stamathioudaki S, Avgerinou G, Tsega A, Katsambas AD. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150–3.

    Article  CAS  PubMed  Google Scholar 

  • Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.

    Article  CAS  PubMed  Google Scholar 

  • Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford). 2005;44:1564–8. Epub 2005 Sep 13.

    Article  CAS  Google Scholar 

  • Truchuelo MT, Boixeda P, Alcantara J, Moreno C, de las Heras E, Olasolo PJ. Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study. J Eur Acad Dermatol Venereol. 2012;26:1272–9.

    Article  CAS  PubMed  Google Scholar 

  • Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol. 2008;64:337–41.

    Article  CAS  PubMed  Google Scholar 

  • Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol. 2007;156:191–2.

    Article  CAS  PubMed  Google Scholar 

  • Ueki H. Koebner phenomenon in lupus erythematosus with special consideration of clinical findings. Autoimmun Rev. 2005;4:219–23.

    Article  PubMed  Google Scholar 

  • Ujiie H, Shimizu T, Ito M, Arita K, Shimizu H. Lupus erythematosus profundus successfully treated with dapsone: review of the literature. Arch Dermatol. 2006;142:399–401.

    Article  PubMed  Google Scholar 

  • Vabre-Latre CM, Bayle P, Marguery MC, Gadroy A, Durand D, Bazex J. Worsening of subacute lupus erythematosus induced by infliximab. Ann Dermatol Venereol. 2005;132:349–53.

    Article  PubMed  Google Scholar 

  • Vena GA, Coviello C, Angelini G. Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus. G Ital Dermatol Venereol. 1989;124:311–5.

    CAS  PubMed  Google Scholar 

  • von Schmiedeberg S, Ronnau AC, Schuppe HC, Specker C, Ruzicka T, Lehmann P. Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus. Hautarzt. 2000;51:82–5.

    Article  Google Scholar 

  • Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131:1981–6.

    Article  CAS  PubMed  Google Scholar 

  • Walker SL, Harland CC. Carbon dioxide laser resurfacing of facial scarring secondary to chronic discoid lupus erythematosus. Br J Dermatol. 2000;143:1101–2.

    Article  CAS  PubMed  Google Scholar 

  • Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum. 1989;18:282–96.

    Article  CAS  PubMed  Google Scholar 

  • Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153:157–62.

    Article  CAS  PubMed  Google Scholar 

  • Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. 2012;21:1007–10.

    Article  CAS  PubMed  Google Scholar 

  • Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol. 2008;22:1–6.

    CAS  PubMed  Google Scholar 

  • Wulf HC, Ullman S. Discoid and subacute lupus erythematosus treated with 0.5% R-salbutamol cream. Arch Dermatol. 2007;143:1589–90.

    Article  PubMed  Google Scholar 

  • Yamada Y, Dekio S, Jidoi J, Ozasa S. Lupus erythematosus profundus-report of a case treated with dapsone. J Dermatol. 1989;16:379–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Muenster, Von-Esmarch-Strasse 58, Muenster, 48149, Germany

    Annegret Kuhn

  2. Interdisciplinary Center for Clinical Trials (IZKS), University Medical Center Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany

    Annegret Kuhn

  3. Division of Immunogenetics, Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Aysche Landmann

Authors
  1. Annegret Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aysche Landmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annegret Kuhn .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Andreas Syggros Hospital University of Athens, Athens, Greece

    Andreas D. Katsambas  & Clio Dessinioti  & 

  2. University of Rome “G. Marconi”, Rome, Italy

    Torello M. Lotti

  3. Centro Studi per la Ricerca Multidisciplinare Rigenerativa (CSRMR), Rome, Italy

    Torello M. Lotti

  4. Unit of Dermatology, University of Pisa, Pisa, Italy

    Angelo Massimiliano D’Erme

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kuhn, A., Landmann, A. (2015). Lupus Erythematosus. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45139-7_55

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45138-0

  • Online ISBN: 978-3-662-45139-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation